ATE328887T1 - Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen - Google Patents
Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungenInfo
- Publication number
- ATE328887T1 ATE328887T1 AT00900497T AT00900497T ATE328887T1 AT E328887 T1 ATE328887 T1 AT E328887T1 AT 00900497 T AT00900497 T AT 00900497T AT 00900497 T AT00900497 T AT 00900497T AT E328887 T1 ATE328887 T1 AT E328887T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- neurodegenerative diseases
- heterocyclic compounds
- condensed heterocyclic
- lesioned
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 230000007850 degeneration Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900061 | 1999-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE328887T1 true ATE328887T1 (de) | 2006-06-15 |
Family
ID=8089290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00900497T ATE328887T1 (de) | 1999-01-19 | 2000-01-13 | Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6576641B2 (enExample) |
| EP (1) | EP1147113B1 (enExample) |
| JP (1) | JP2002535334A (enExample) |
| CN (1) | CN1147490C (enExample) |
| AT (1) | ATE328887T1 (enExample) |
| AU (1) | AU776276B2 (enExample) |
| CA (1) | CA2353903A1 (enExample) |
| DE (1) | DE60028538T2 (enExample) |
| NZ (1) | NZ512289A (enExample) |
| WO (1) | WO2000043397A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311386T1 (de) * | 2001-09-24 | 2005-12-15 | Bayer Pharmaceuticals Corp | Verfahren zur herstellung von 1,5,6,7- tetrahydropyrrolo(3,2-c)derivaten zur behandlung der fettleibigkeit |
| KR100553398B1 (ko) | 2004-03-12 | 2006-02-16 | 한미약품 주식회사 | 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체 |
| KR102074089B1 (ko) | 2009-12-04 | 2020-02-05 | 선오비온 파마슈티컬스 인코포레이티드 | 다환형 화합물 및 이의 사용 방법 |
| JP7187437B2 (ja) | 2016-07-29 | 2022-12-12 | サノビオン ファーマシューティカルズ インク | 化合物および組成物ならびにそれらの使用 |
| EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
| MX390141B (es) | 2017-02-16 | 2025-03-20 | Sunovion Pharmaceuticals Inc | Metodos para tratar esquizofrenia |
| SG11202000669VA (en) | 2017-08-02 | 2020-02-27 | Sunovion Pharmaceuticals Inc | Isochroman compounds and uses thereof |
| CN112135827B (zh) | 2018-02-16 | 2024-01-12 | 赛诺维信制药公司 | 盐、晶型及其制备方法 |
| KR20210139376A (ko) | 2019-03-14 | 2021-11-22 | 선오비온 파마슈티컬스 인코포레이티드 | 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물 |
| WO2021211489A1 (en) | 2020-04-14 | 2021-10-21 | Sunovion Pharmaceuticals Inc. | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders |
| PE20242113A1 (es) | 2021-10-14 | 2024-10-28 | Incyte Corp | Compuestos de quinolina como inhibidores de kras |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2395028A2 (fr) * | 1977-06-22 | 1979-01-19 | Centre Etd Ind Pharma | Derives pyridiniques, leur preparation et leurs application therapeutique |
| FR2566775B1 (fr) | 1984-06-27 | 1986-10-31 | Synthelabo | Derives de tetrahydro-4,5,6,7 furo ou 1h-pyrrolo(2,3-c)pyridine, leur preparation et leur application en therapeutique |
| FR2570701B1 (fr) * | 1984-09-27 | 1987-05-22 | Synthelabo | Derives de furo(3,2-c)pyridines, leur preparation et leur application en therapeutique |
| FR2635977B1 (fr) * | 1988-09-07 | 1992-05-15 | Synthelabo | Utilisation de derives de tetrahydro-4,5,6,7 furopyridines pour obtenir des medicaments destines au traitement de l'obesite |
| GB8921465D0 (en) * | 1989-09-22 | 1989-11-08 | Fujisawa Pharmaceutical Co | Bicyclic amine compound and a process for the preparation thereof |
| FR2652579B1 (fr) * | 1989-10-02 | 1992-01-24 | Sanofi Sa | Derives d'hydroxy-2 thiophene et furanne condenses avec un cycle azote, sur procede de preparation et leur application en therapeutique. |
| FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
| CA2200469A1 (en) * | 1994-10-11 | 1996-04-18 | Takeda Chemical Industries, Ltd. | Condensed compounds, their production and use |
| CN1250528C (zh) * | 1995-09-11 | 2006-04-12 | 阿温蒂斯药物公司 | 环状硝酮和含有它们的药用组合物 |
-
2000
- 2000-01-13 EP EP00900497A patent/EP1147113B1/en not_active Expired - Lifetime
- 2000-01-13 CN CNB008027080A patent/CN1147490C/zh not_active Expired - Fee Related
- 2000-01-13 DE DE60028538T patent/DE60028538T2/de not_active Expired - Lifetime
- 2000-01-13 CA CA002353903A patent/CA2353903A1/en not_active Abandoned
- 2000-01-13 NZ NZ512289A patent/NZ512289A/xx not_active IP Right Cessation
- 2000-01-13 JP JP2000594813A patent/JP2002535334A/ja active Pending
- 2000-01-13 AU AU30333/00A patent/AU776276B2/en not_active Ceased
- 2000-01-13 WO PCT/DK2000/000012 patent/WO2000043397A1/en not_active Ceased
- 2000-01-13 AT AT00900497T patent/ATE328887T1/de not_active IP Right Cessation
-
2001
- 2001-06-07 US US09/875,019 patent/US6576641B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002535334A (ja) | 2002-10-22 |
| WO2000043397A1 (en) | 2000-07-27 |
| EP1147113A1 (en) | 2001-10-24 |
| DE60028538D1 (de) | 2006-07-20 |
| CN1336929A (zh) | 2002-02-20 |
| US20020013336A1 (en) | 2002-01-31 |
| EP1147113B1 (en) | 2006-06-07 |
| AU776276B2 (en) | 2004-09-02 |
| NZ512289A (en) | 2003-06-30 |
| AU3033300A (en) | 2000-08-07 |
| US6576641B2 (en) | 2003-06-10 |
| CN1147490C (zh) | 2004-04-28 |
| DE60028538T2 (de) | 2007-06-21 |
| CA2353903A1 (en) | 2000-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE255888T1 (de) | Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten | |
| DE602004010419D1 (de) | Triazaspiropiperidinderivate zur verwendung als glyt-1-inhibitoren bei der behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| ATE463492T1 (de) | Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes | |
| ATE380548T1 (de) | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie | |
| DE60210093D1 (de) | Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und -tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes | |
| ATE554756T1 (de) | Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE60027913D1 (de) | 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE328887T1 (de) | Kondensierte heterocyclische verbindungen und ihre verwendung zur behandlung von neurodegenerativen erkrankungen | |
| DE60233433D1 (de) | PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE279401T1 (de) | Verbindungen und verfahren zur behandlung von asthma, allergie und entzündlichen erkrankungen | |
| EP1117395A4 (en) | COMPOUNDS FOR THE TREATMENT OF ESTROGEN-RELATED DISEASES, METHODS OF PRODUCTION AND METHODS OF USE | |
| DE69912670D1 (de) | Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
| ATE290866T1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
| PT1255734E (pt) | Derivados de isatina com actividade neurotrofica | |
| ATE374197T1 (de) | Indolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| DE60318081D1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
| DE60005685D1 (de) | Oxazinocarbazole zur behandlung von cns-erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |